OTIC - Otonomy - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-9.119M

Cash

40.15M

Avg Qtr Burn

-11.69M

Short % of Float

3.29%

Insider Ownership

7.67%

Institutional Own.

1.43%

Qtr Updated

09/30/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OTIPRIO (ciprofloxacin otic suspension) 6% Details Bilateral Otitis Media and AOE (Acute Otitis Externa)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTO-413 Details Tinnitus, Ear illness/ disorder, Hearing loss	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTIVIDEX® Details Ménière's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTO-313 Details Tinnitus, Ear illness/ disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.